Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/6/2025

Pneumonitis: Definition, Clinical Understanding, and Management

Introduction to Pneumonitis

  • Pneumonitis is defined as focal or diffuse inflammation of the lung parenchyma that can be caused by various agents including drugs, environmental exposures, and immune checkpoint inhibitors, as stated by the American Thoracic Society 1, 2

Types and Causes of Pneumonitis

  • Drug-related pneumonitis (DRP) is one of the most common forms, with cancer drugs, drugs for autoimmune diseases, amiodarone, and antibiotics being frequent causes, according to the American College of Chest Physicians 1
  • Immune-related interstitial lung disease (IR-ILD) or immune-related pneumonitis can occur with immune checkpoint inhibitor therapy, as reported by the European Society for Medical Oncology 2, 3

Clinical Presentation

  • Pneumonitis can present with varying severity, from asymptomatic to life-threatening, as noted by the American College of Chest Physicians 1
  • Fatigue with activities of daily living is a common symptom, as stated by the Society for Immunotherapy of Cancer 2, 4

Diagnostic Features

  • Temporal relationship between exposure to potential causative agent and symptom onset is crucial for diagnosis, as emphasized by the American College of Chest Physicians 1, 5
  • Chest CT is essential and should be performed as early as possible when pneumonitis is suspected, according to the American College of Radiology 1
  • Common radiologic patterns include consolidation, as reported by the Journal for ImmunoTherapy of Cancer 4
  • Mosaic attenuation is a characteristic finding in hypersensitivity pneumonitis, as noted by the American College of Chest Physicians 1, 5, 6

Differential Diagnosis

  • Pneumonitis must be distinguished from pneumonia (infectious), diffuse alveolar hemorrhage, pulmonary edema, radiation pneumonitis, and pulmonary metastases, as stated by the American College of Chest Physicians 7

Management

  • The primary approach is to identify and remove the causative agent, as recommended by the American College of Chest Physicians 1
  • Discontinuation of the offending drug and corticosteroids for moderate to severe cases are recommended for drug-related pneumonitis, according to the American College of Chest Physicians 1, 2
  • Grading of severity guides management for immune checkpoint inhibitor-related pneumonitis, as reported by the European Society for Medical Oncology 3

Prognosis

  • If unchecked, pneumonitis can lead to pulmonary fibrosis, as noted by the American College of Chest Physicians 6
  • Early recognition and treatment are essential to prevent progression to chronic, irreversible disease, as emphasized by the American College of Chest Physicians 1

Immune Checkpoint Inhibitor-Related Pneumonitis and Other Causes

Incidence and Risk Factors

  • Immune checkpoint inhibitors can cause pneumonitis with an overall incidence of <5% for monotherapy, with higher rates (up to 10%) reported with combination therapies, according to the Society for Immunotherapy of Cancer 8, 9
  • PD-1 inhibitors have a higher incidence of pneumonitis (3.6%) compared to PD-L1 inhibitors (1.3%), as reported by the Journal for ImmunoTherapy of Cancer 8, 10
  • Higher risk of pneumonitis is observed in patients with non-small cell lung cancer compared to melanoma patients, as noted by the Journal for ImmunoTherapy of Cancer and the Journal of Clinical Oncology 9, 10

Pathophysiology and Clinical Presentation

  • Radiographic patterns of pneumonitis include cryptogenic organizing pneumonia (COP), nonspecific interstitial pneumonitis (NSIP), hypersensitivity pneumonitis (HP), or usual interstitial pneumonitis (UIP)/pulmonary fibrosis, according to the Journal for ImmunoTherapy of Cancer 8, 10
  • Pulmonary sarcoidosis and sarcoid-like granulomatous reactions can occur following immune checkpoint inhibitor therapy, characterized by increased numbers of T helper 17 (Th17.1) cells in bronchoalveolar lavage fluid, as reported by the Journal for ImmunoTherapy of Cancer 8, 10
  • Hypersensitivity pneumonitis is caused by inhalation of various environmental antigens leading to an exaggerated immune response, characterized by CD4+ T cell differentiation into Th1 cells promoting granuloma formation, according to the American College of Chest Physicians 11

Diagnostic Considerations

  • Bronchoalveolar lavage (BAL) cellular analysis can help differentiate between causes of pneumonitis, with BAL cell differential counts with >15% lymphocytes, >3% neutrophils, >1% eosinophils, and >0.5% mast cells representing different cellular patterns with diagnostic implications, as noted by the American Thoracic Society 12

Clinical Implications and Management

  • For immune checkpoint inhibitor-related pneumonitis, treatment is based on severity grading, with drug withdrawal as the mainstay for all grades, and corticosteroids indicated for moderate to severe cases, with additional immunosuppression (infliximab, cyclophosphamide) for recalcitrant disease, according to the European Society for Medical Oncology and the Society for Immunotherapy of Cancer 8, 13

REFERENCES